Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

ClinicalTrials.gov ID

NCT07509112

Lead Sponsor

Kirby InstituteOTHER_GOV

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

40Estimated

Last Update Posted

Jun 26, 2026Actual

Start Date

Sep 2026Estimated

Primary Completion Date

Jan 2027Estimated

Completion Date

Mar 2027Estimated

Official Title

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Brief Summary

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

Detailed Description

Methamphetamine use disorder is a major public health concern in Australia and globally, associated with high morbidity and limited treatment options. People with methamphetamine use disorder frequently face social marginalisation, psychiatric comorbidity, housing instability, and criminal justice involvement, contributing to poor treatment access and outcomes. At present, no pharmacotherapies have been approved for the treatment of methamphetamine use disorder. While several agents have demonstrated preliminary promise-including mirtazapine, which has shown consistent findings across trials-none have yet established sufficient efficacy to achieve regulatory approval. Ongoing registrational trials, such as those evaluating extended-release naltrexone combined with bupropion, and mirtazapine, may clarify the potential role of these agents in clinical practice.

Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide, are approved for diabetes and obesity and have central effects on reward pathways relevant to addiction. Preclinical studies show GLP-1 agonists reduce stimulant-related dopamine signalling and drug-seeking behaviour. Observational studies in humans suggest semaglutide may reduce risk of alcohol use disorder, hospitalisations related to substance use, and overdose, and a recent randomised controlled trial demonstrated reductions in cravings, and use of, alcohol and tobacco. However, no trials have yet evaluated semaglutide in methamphetamine use disorder. This pilot study will be the first to assess its feasibility, safety, and preliminary efficacy for methamphetamine use disorder.

• Methamphetamine Use Disorder

• 12 weeks of weekly subcutaneous semaglutide injection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Has provided voluntary, written informed consent;
2. Aged 18 years or older;
3. Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria);
4. Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine/methamphetamine;
5. Willing and able to comply with study procedures and follow-up visits;
6. People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end.

Exclusion Criteria:

1. Uncontrolled medical or psychiatric conditions that may interfere with participation;
2. Body mass index less than 22 kg/m2;
3. Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c >6.5 at screening);
4. Currently taking a GLP-1 receptor agonist;
5. Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information;
6. Current enrolment in another interventional trial;
7. Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy
8. History of pancreatitis;
9. History of medullary thyroid cancer;
10. Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures;
11. Currently experiencing psychosis or current active suicidality
12. Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Kirby InstituteOTHER_GOV

mark.daglish@health.qld.gov.au+617 3837 5764

Katherine.Senior@sa.gov.au+618 8325 8111

michael.christmass@health.wa.gov.au+6189430 5966

• Glutide for Ending Methamphetamine

  NCT07204249

  RecruitingInterventionalPhase 2Updated Jun 3, 2026
• GLP-1R Agonist Treatment for Opioid Use Disorder

  NCT06548490

  RecruitingInterventionalPhase 2Updated Aug 28, 2026
• Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

  NCT07227948

  RecruitingInterventionalPhase 2Updated Mar 19, 2026
• Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

  NCT06691243

  Active, not recruitingInterventionalPhase 2Updated Sep 10, 2026
• Semaglutide for Alcohol Use Disorder

  NCT05520775

  CompletedInterventionalPhase 2Updated Apr 2, 2025
• Semaglutide Therapy for Alcohol Reduction - Tulsa

  NCT05891587

  CompletedInterventionalPhase 2Updated Dec 17, 2025